 Julie Goddard
Concepts (153)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Head and Neck Neoplasms | 7 | 2023 | 558 | 0.990 |
Why?
| | Free Tissue Flaps | 4 | 2023 | 45 | 0.980 |
Why?
| | Otolaryngologists | 1 | 2018 | 13 | 0.560 |
Why?
| | Microsurgery | 1 | 2018 | 72 | 0.540 |
Why?
| | Carcinoma, Squamous Cell | 6 | 2019 | 641 | 0.540 |
Why?
| | Parotitis | 1 | 2017 | 6 | 0.520 |
Why?
| | Parotid Gland | 1 | 2017 | 17 | 0.520 |
Why?
| | Vascular Malformations | 1 | 2017 | 50 | 0.490 |
Why?
| | Antibiotic Prophylaxis | 1 | 2017 | 129 | 0.490 |
Why?
| | Surgical Wound Infection | 1 | 2017 | 316 | 0.420 |
Why?
| | Lymph Node Excision | 2 | 2019 | 173 | 0.390 |
Why?
| | Thyroidectomy | 1 | 2013 | 91 | 0.380 |
Why?
| | Neoplasm Recurrence, Local | 3 | 2020 | 1137 | 0.360 |
Why?
| | Carcinoma | 1 | 2013 | 228 | 0.340 |
Why?
| | Practice Patterns, Physicians' | 1 | 2018 | 1356 | 0.290 |
Why?
| | Thyroid Neoplasms | 1 | 2013 | 345 | 0.290 |
Why?
| | Eyelids | 1 | 2022 | 41 | 0.180 |
Why?
| | Orbit | 1 | 2022 | 64 | 0.180 |
Why?
| | Laryngectomy | 2 | 2018 | 16 | 0.170 |
Why?
| | Margins of Excision | 2 | 2018 | 51 | 0.170 |
Why?
| | Laryngeal Neoplasms | 2 | 2020 | 35 | 0.160 |
Why?
| | Oropharynx | 1 | 2020 | 46 | 0.160 |
Why?
| | Lymphatic Metastasis | 2 | 2019 | 333 | 0.160 |
Why?
| | Mouth | 1 | 2020 | 88 | 0.160 |
Why?
| | Larynx | 1 | 2020 | 56 | 0.160 |
Why?
| | Tracheal Neoplasms | 1 | 2019 | 12 | 0.150 |
Why?
| | Survival Rate | 3 | 2019 | 2089 | 0.150 |
Why?
| | Pharyngectomy | 1 | 2018 | 4 | 0.140 |
Why?
| | Lymph Nodes | 2 | 2019 | 502 | 0.140 |
Why?
| | Radiosurgery | 1 | 2022 | 400 | 0.140 |
Why?
| | Reoperation | 2 | 2018 | 630 | 0.140 |
Why?
| | Papillomavirus Infections | 1 | 2022 | 345 | 0.140 |
Why?
| | Mouth Neoplasms | 1 | 2019 | 90 | 0.140 |
Why?
| | Oropharyngeal Neoplasms | 1 | 2018 | 55 | 0.130 |
Why?
| | Medicare | 2 | 2020 | 886 | 0.130 |
Why?
| | Nomograms | 1 | 2018 | 59 | 0.130 |
Why?
| | Carcinoma, Adenosquamous | 1 | 2017 | 9 | 0.130 |
Why?
| | Parotid Diseases | 1 | 2017 | 3 | 0.130 |
Why?
| | Carcinoma, Adenoid Cystic | 1 | 2017 | 19 | 0.130 |
Why?
| | Nose Neoplasms | 1 | 2017 | 21 | 0.130 |
Why?
| | Carcinoma, Mucoepidermoid | 1 | 2017 | 17 | 0.130 |
Why?
| | Surgical Flaps | 1 | 2018 | 142 | 0.130 |
Why?
| | Canada | 1 | 2018 | 428 | 0.130 |
Why?
| | Paranasal Sinus Neoplasms | 1 | 2017 | 29 | 0.130 |
Why?
| | Parotid Neoplasms | 1 | 2017 | 15 | 0.130 |
Why?
| | Health Services Needs and Demand | 1 | 2019 | 280 | 0.130 |
Why?
| | Induction Chemotherapy | 1 | 2017 | 87 | 0.120 |
Why?
| | Microvessels | 1 | 2017 | 99 | 0.120 |
Why?
| | Vocal Cord Dysfunction | 1 | 2016 | 9 | 0.120 |
Why?
| | Evidence-Based Medicine | 1 | 2018 | 732 | 0.110 |
Why?
| | Humans | 20 | 2023 | 144759 | 0.110 |
Why?
| | Fellowships and Scholarships | 1 | 2018 | 357 | 0.100 |
Why?
| | Tomography, Optical Coherence | 1 | 2016 | 271 | 0.100 |
Why?
| | Recurrence | 1 | 2017 | 1135 | 0.100 |
Why?
| | Ultrasonography | 1 | 2017 | 770 | 0.090 |
Why?
| | Postoperative Complications | 3 | 2023 | 2919 | 0.090 |
Why?
| | Disease-Free Survival | 3 | 2020 | 769 | 0.090 |
Why?
| | Female | 11 | 2019 | 78271 | 0.090 |
Why?
| | Male | 12 | 2022 | 72315 | 0.090 |
Why?
| | Aged | 10 | 2020 | 25913 | 0.090 |
Why?
| | Middle Aged | 9 | 2020 | 35875 | 0.080 |
Why?
| | United States | 5 | 2020 | 15966 | 0.080 |
Why?
| | Melanoma | 1 | 2017 | 761 | 0.080 |
Why?
| | Adult | 8 | 2022 | 40449 | 0.080 |
Why?
| | Neoplasm Staging | 3 | 2019 | 1462 | 0.070 |
Why?
| | Retrospective Studies | 7 | 2023 | 17066 | 0.070 |
Why?
| | Magnetic Resonance Imaging | 2 | 2017 | 3863 | 0.070 |
Why?
| | Databases, Factual | 3 | 2019 | 1486 | 0.070 |
Why?
| | Anion Transport Proteins | 1 | 2006 | 8 | 0.060 |
Why?
| | Neoadjuvant Therapy | 2 | 2022 | 462 | 0.060 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2013 | 985 | 0.060 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 2016 | 1953 | 0.060 |
Why?
| | Directed Molecular Evolution | 1 | 2006 | 29 | 0.060 |
Why?
| | Cross-Sectional Studies | 1 | 2018 | 5868 | 0.060 |
Why?
| | Time Factors | 1 | 2017 | 7173 | 0.060 |
Why?
| | Radiotherapy, Adjuvant | 2 | 2017 | 222 | 0.060 |
Why?
| | Alphapapillomavirus | 2 | 2018 | 35 | 0.060 |
Why?
| | Chemotherapy, Adjuvant | 2 | 2017 | 421 | 0.060 |
Why?
| | Surveys and Questionnaires | 1 | 2018 | 6048 | 0.060 |
Why?
| | Prognosis | 3 | 2019 | 4282 | 0.050 |
Why?
| | Combined Modality Therapy | 2 | 2019 | 1266 | 0.050 |
Why?
| | Survival Analysis | 2 | 2019 | 1382 | 0.050 |
Why?
| | Proportional Hazards Models | 2 | 2017 | 1325 | 0.050 |
Why?
| | Multivariate Analysis | 2 | 2017 | 1539 | 0.050 |
Why?
| | Evolution, Molecular | 1 | 2006 | 514 | 0.050 |
Why?
| | Anastomosis, Surgical | 1 | 2023 | 157 | 0.050 |
Why?
| | Optic Nerve | 1 | 2022 | 67 | 0.040 |
Why?
| | Injections | 1 | 2022 | 196 | 0.040 |
Why?
| | Heparin | 1 | 2023 | 244 | 0.040 |
Why?
| | Tissue Plasminogen Activator | 1 | 2023 | 244 | 0.040 |
Why?
| | Fibrinolytic Agents | 1 | 2023 | 291 | 0.040 |
Why?
| | Fluorodeoxyglucose F18 | 1 | 2020 | 156 | 0.040 |
Why?
| | Positron-Emission Tomography | 1 | 2020 | 323 | 0.040 |
Why?
| | Hypopharynx | 1 | 2018 | 2 | 0.040 |
Why?
| | Operative Time | 1 | 2018 | 175 | 0.030 |
Why?
| | Preoperative Period | 1 | 2018 | 149 | 0.030 |
Why?
| | Anticoagulants | 1 | 2023 | 722 | 0.030 |
Why?
| | Postoperative Period | 1 | 2018 | 354 | 0.030 |
Why?
| | Chemoradiotherapy, Adjuvant | 1 | 2017 | 44 | 0.030 |
Why?
| | National Cancer Institute (U.S.) | 1 | 2017 | 52 | 0.030 |
Why?
| | Otorhinolaryngologic Surgical Procedures | 1 | 2017 | 37 | 0.030 |
Why?
| | Biopsy, Fine-Needle | 1 | 2017 | 68 | 0.030 |
Why?
| | Office Visits | 1 | 2017 | 90 | 0.030 |
Why?
| | Vocal Cords | 1 | 2016 | 26 | 0.030 |
Why?
| | Critical Care | 1 | 2022 | 695 | 0.030 |
Why?
| | Aged, 80 and over | 2 | 2019 | 8265 | 0.030 |
Why?
| | Chemoradiotherapy | 1 | 2017 | 237 | 0.030 |
Why?
| | Neoplasm Invasiveness | 1 | 2017 | 508 | 0.030 |
Why?
| | Antibodies, Monoclonal | 1 | 2022 | 1519 | 0.030 |
Why?
| | Propensity Score | 1 | 2017 | 367 | 0.030 |
Why?
| | Laryngoscopy | 1 | 2016 | 117 | 0.030 |
Why?
| | Cisplatin | 1 | 2016 | 334 | 0.030 |
Why?
| | Kaplan-Meier Estimate | 1 | 2017 | 965 | 0.030 |
Why?
| | Analysis of Variance | 1 | 2017 | 1306 | 0.030 |
Why?
| | Socioeconomic Factors | 1 | 2019 | 1326 | 0.030 |
Why?
| | Epithelial Cells | 1 | 2020 | 1125 | 0.030 |
Why?
| | Program Evaluation | 1 | 2018 | 948 | 0.030 |
Why?
| | Healthcare Disparities | 1 | 2020 | 727 | 0.020 |
Why?
| | Receptor, Notch2 | 1 | 2013 | 15 | 0.020 |
Why?
| | Gonanes | 1 | 2013 | 28 | 0.020 |
Why?
| | Receptor, Notch1 | 1 | 2013 | 64 | 0.020 |
Why?
| | Cetuximab | 1 | 2013 | 111 | 0.020 |
Why?
| | Treatment Outcome | 2 | 2018 | 11679 | 0.020 |
Why?
| | Length of Stay | 1 | 2018 | 1337 | 0.020 |
Why?
| | Phosphatidylinositol 3-Kinases | 1 | 2013 | 380 | 0.020 |
Why?
| | Blotting, Western | 1 | 2013 | 1187 | 0.020 |
Why?
| | Xenograft Model Antitumor Assays | 1 | 2013 | 928 | 0.020 |
Why?
| | ErbB Receptors | 1 | 2013 | 627 | 0.020 |
Why?
| | Quality Improvement | 1 | 2018 | 1289 | 0.020 |
Why?
| | Follow-Up Studies | 1 | 2019 | 5408 | 0.020 |
Why?
| | Immunohistochemistry | 1 | 2013 | 1716 | 0.020 |
Why?
| | Computational Biology | 1 | 2013 | 680 | 0.020 |
Why?
| | Risk Assessment | 1 | 2017 | 3671 | 0.020 |
Why?
| | Renilla | 1 | 2006 | 3 | 0.020 |
Why?
| | Organic Anion Transporters | 1 | 2006 | 13 | 0.020 |
Why?
| | Gerbillinae | 1 | 2006 | 72 | 0.020 |
Why?
| | Tomography, X-Ray Computed | 1 | 2017 | 2730 | 0.020 |
Why?
| | Protein Interaction Mapping | 1 | 2006 | 104 | 0.020 |
Why?
| | Cohort Studies | 1 | 2017 | 5960 | 0.010 |
Why?
| | Protein Structure, Secondary | 1 | 2006 | 369 | 0.010 |
Why?
| | Structure-Activity Relationship | 1 | 2006 | 570 | 0.010 |
Why?
| | Infant, Newborn | 1 | 2017 | 6429 | 0.010 |
Why?
| | Risk Factors | 1 | 2019 | 10779 | 0.010 |
Why?
| | Amino Acid Sequence | 1 | 2006 | 2155 | 0.010 |
Why?
| | Infant | 1 | 2017 | 10034 | 0.010 |
Why?
| | Molecular Sequence Data | 1 | 2006 | 2930 | 0.010 |
Why?
| | Child, Preschool | 1 | 2017 | 11787 | 0.010 |
Why?
| | Cell Line | 1 | 2006 | 2882 | 0.010 |
Why?
| | Young Adult | 1 | 2017 | 14105 | 0.010 |
Why?
| | Animals | 2 | 2013 | 38058 | 0.010 |
Why?
| | Adolescent | 1 | 2017 | 22428 | 0.010 |
Why?
| | Child | 1 | 2017 | 22633 | 0.010 |
Why?
| | Mice | 1 | 2013 | 18339 | 0.010 |
Why?
|
|
Goddard's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|